ENTX Logo

Entera Bio Ltd (ENTX) Stock Forecast & Price Prediction

Live ENTX Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Biotechnology

$2.43

+0.14 (6.11%)

12 Month Price Forecast For ENTX

$2.43
Current Price
$89.50M
Market Cap
1 Ratings
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to ENTX Price Forecasts

+311.5%
To High Target of $10.00
+311.5%
To Median Target of $10.00
+311.5%
To Low Target of $10.00

ENTX Price Momentum

0.0%
1 Week Change
+6.6%
1 Month Change
+131.4%
1 Year Change
+14.6%
Year-to-Date Change
-27.5%
From 52W High of $3.35
+196.3%
From 52W Low of $0.82

๐Ÿค” Considering Entera (ENTX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 2:05 PM UTC

ENTX Analyst Ratings & Price Targets

Based on our analysis of 3 Wall Street analysts, ENTX has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). Currently trading at $2.43, the median forecast implies a 311.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 311.5% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 311.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ENTX Analyst Consensus

1
Buy
0
Hold
0
Sell

ENTX Price Target Range

Low
$10.00
Average
$10.00
High
$10.00
Current: $2.43

Latest ENTX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ENTX.

Date Firm Analyst Rating Change Price Target
Nov 11, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Oct 7, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Sep 27, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Aug 12, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Jun 5, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
May 14, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
May 13, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Apr 2, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $10.00
Dec 11, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Sep 13, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Sep 11, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
May 8, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Apr 4, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Mar 28, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $10.00
Sep 6, 2022 HC Wainwright & Co. Raghuram Selvaraju Buy Initiates $10.00
Jul 19, 2022 B. Riley Securities Kalpit Patel Buy Maintains $5.00
Jun 16, 2021 B. Riley Securities Buy Initiates $0.00
Mar 22, 2021 Aegis Capital Buy Initiates $0.00
Aug 3, 2018 Maxim Group Buy Initiates $0.00

Stocks Similar to Entera Bio Ltd

The following stocks are similar to Entera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Entera Bio Ltd (ENTX) Financial Data

Entera Bio Ltd has a market capitalization of $89.50M with a P/E ratio of -7.8x. The company generates $99,000 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is -26.3% quarter-over-quarter, while maintaining an operating margin of -7,192.9% and return on equity of -144.7%.

Valuation Metrics

Market Cap $89.50M
Enterprise Value $82.90M
P/E Ratio -7.8x
PEG Ratio -4.4x
Price/Sales 904.1x

Growth & Margins

Revenue Growth (YoY) -26.3%
Gross Margin N/A
Operating Margin -7,192.9%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +7.7%
Current Ratio 6.6x
Debt/Equity 4.8x
ROE -144.7%
ROA -70.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Entera Bio Ltd logo

Entera Bio Ltd (ENTX) Company Overview

About Entera Bio Ltd

What They Do

Develops oral peptide therapies for medical needs.

Business Model

Entera Bio Ltd. operates as a clinical stage biopharmaceutical company, focusing on creating oral delivery systems for peptide and protein therapies. The company generates revenue through partnerships and collaborations, particularly leveraging its proprietary N-Tab technology to develop innovative treatments like EB613 for osteoporosis and EB612 for hypoparathyroidism, among others.

Additional Information

Founded in 2009 and based in Jerusalem, Israel, Entera Bio has advanced several product candidates to various stages of development, including a Phase 3 trial for its osteoanabolic therapy. The company's commitment to improving patient outcomes through non-injection therapies positions it well within the growing biopharmaceutical market.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

17

CEO

Ms. Miranda J. Toledano M.B.A.

Country

Israel

IPO Year

2018

Entera Bio Ltd (ENTX) Latest News & Analysis

ENTX stock latest news image
Quick Summary

Entera Bio Ltd. (NASDAQ: ENTX) will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11-12, 2025, for investor meetings.

Why It Matters

Entera Bio's participation in a major healthcare conference signals potential investor interest and highlights its focus on innovative drug delivery, which could impact stock performance and market perception.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENTX stock latest news image
Quick Summary

Entera Bio Ltd. (NASDAQ: ENTX) reported its Q3 2024 financial results and business updates, focusing on its development of oral peptides and small therapeutic proteins.

Why It Matters

Entera Bio's quarterly financial results and updates may signal its growth prospects and impact stock performance, influencing investment decisions in the biotech sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENTX stock latest news image
Quick Summary

Entera Bio Ltd. (ENTX) reported a quarterly loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.05 loss.

Why It Matters

Entera Bio's larger-than-expected quarterly loss may signal operational challenges, potentially impacting investor confidence and future stock performance.

Source: Zacks Investment Research
Market Sentiment: Negative
ENTX stock latest news image
Quick Summary

Entera and OPKO Health report positive pharmacokinetic/pharmacodynamic results in their collaboration to develop an oral dual agonist for GLP-1 and glucagon peptides.

Why It Matters

Positive PK/PD results from Entera and OPKO Health could indicate potential for a groundbreaking weight management drug, impacting market share and stock performance in the biotech sector.

Source: Zacks Investment Research
Market Sentiment: Positive
ENTX stock latest news image
Quick Summary

Entera Bio Ltd. and OPKO Health announced positive topline PK/PD results for their oral dual agonist GLP-1/glucagon peptide aimed at treating obesity and metabolic disorders.

Why It Matters

The collaboration between Entera Bio and OPKO could lead to a groundbreaking obesity treatment, potentially increasing their market value and attracting investor interest in the biotech sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENTX stock latest news image
Quick Summary

Entera Bio Ltd. (ENTX) and argenex SE (ARGX) are being compared to their sector's performance for the current year. Specific performance metrics are not provided in the excerpt.

Why It Matters

Performance comparisons reveal trends in sector strength and individual stock resilience, informing investment decisions and potential shifts in market sentiment for ENTX and ARGX.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About ENTX Stock

What is Entera Bio Ltd's (ENTX) stock forecast for 2025?

Based on our analysis of 3 Wall Street analysts, Entera Bio Ltd (ENTX) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.

Is ENTX stock a good investment in 2025?

According to current analyst ratings, ENTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.43. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ENTX stock?

Wall Street analysts predict ENTX stock could reach $10.00 in the next 12 months. This represents a 311.5% increase from the current price of $2.43. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Entera Bio Ltd's business model?

Entera Bio Ltd. operates as a clinical stage biopharmaceutical company, focusing on creating oral delivery systems for peptide and protein therapies. The company generates revenue through partnerships and collaborations, particularly leveraging its proprietary N-Tab technology to develop innovative treatments like EB613 for osteoporosis and EB612 for hypoparathyroidism, among others.

What is the highest forecasted price for ENTX Entera Bio Ltd?

The highest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 311.5% increase from the current price of $2.43.

What is the lowest forecasted price for ENTX Entera Bio Ltd?

The lowest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 311.5% increase from the current price of $2.43.

What is the overall ENTX consensus from analysts for Entera Bio Ltd?

The overall analyst consensus for ENTX is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.

How accurate are ENTX stock price projections?

Stock price projections, including those for Entera Bio Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.